AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say

Pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca got a ratings boost from Berenberg analysts from their respective returns on R&D investment, and ability to withstand pressure coming from recent U.S price reform.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.